Shots:

• The P-II study involves assessing the safety & immunogenicity of the CoVLP vs PBO in 306 subjects aged ≥18yrs. with two age groups (18-64yrs & over 65yrs.) across the US & Canada
• Results: vaccine induced humoral immune response of similar strength in both age cohorts after two doses- both age cohorts responded with NAb titers that were about 10 times higher than those in a panel of sera from patients recovering from COVID-19- well tolerated with acceptable safety profile
• CoVLP has received the US FDA’s FTD while Health Canada has initiated a review of Medicago’s COVID-19 rolling submission under the interim order

  Ref: GSK | Image: GSK